In ongoing litigation over Celltrion and Pfizer’s infliximab biosimilar, Inflectra, a Massachusetts district court has granted Celltrion’s motion for leave to file a motion for summary judgment of non-infringement.
In ongoing litigation over Celltrion and Pfizer’s infliximab biosimilar, Inflectra, a Massachusetts district court has granted Celltrion’s motion for leave to file a motion for summary judgment of non-infringement.
Janssen, maker of the reference infliximab, Remicade, has claimed that the biosimilar developer infringed on a patent, which covers chemically defined media compositions for the culture of eukaryotic cells, in producing Inflectra.
In support of its motion, Celltrion said that Janssen’s patent is not new and that the court should terminate the case based on ensnarement, or the principle that prior art (elements of patented information that are already publicly available) restricts the scope of what the alleging party can assert under the doctrine of equivalents (a legal rule holding that, while a product may not literally infringe on a patented invention, the product may have elements that are equivalent to those described in a patent).
According to Celltrion, if Janssen wants to claim that Celltrion infringed on Janssen’s patent through the doctrine of equivalents, Janssen should have the burden of proving that the scope of equivalency does not encompass any prior art related to the patent.
“There is every reason for the Court to consider ensnarement on a motion for summary judgment” in this case, according to the motion, especially given the fact that GlaxoSmithKline has already disclosed the same ingredients, at concentrations that overlap heavily with Janssen’s patented ingredients and concentrations, elsewhere. These overlapping ranges establish a case for the obviousness of Janssen’s invention, says Celltrion.
The motion proposes a deadline of May 10, 2018, for Janssen to file its opposition, after which Celltrion would file its reply brief by May 28, 2018.
In October of 2017, the court denied Celltrion’s motion to dismiss this case for lack of standing.
Biosimilars in America: Overcoming Barriers and Maximizing Impact
July 21st 2024Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.
Hesitancy in MENA Nations to Adopt WHO Biosimilar Guidelines Hinders Market Development
July 17th 2024The World Health Organization’s (WHO) new guidelines for biosimilar approvals aim to save time and money for manufacturers in the Middle East and North Africa (MENA), but hesitancy among nations to adopt the guidelines is stifling market development of biosimilars.
Biosimilars Policy Roundup for April 2024—Podcast Edition
May 5th 2024On this episode of Not So Different, The Center for Biosimilars® glances back at all the major biosimilar policy updates from April, including 2 FDA approvals, 1 European approval, and several insights into possible policy changes from the Festival of Biologics USA conference.